BLOOMFIELD, N.J.--(BUSINESS WIRE)--Alfacell Corporation (NASDAQ: ACEL) today announced the presentation of preclinical findings based on histological evidence and provide further support for the potential anti-tumor activity of ONCONASE® (ranpirnase) in non-small-cell lung cancer (NSCLC). The new data, which will help guide ongoing development of the NSCLC clinical program, demonstrated the following:
